Navigation Links
Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Date:9/26/2007

technology and is under international development for the management of post-operative pain following moderate/major abdominal, gynecological, thoracic, and orthopedic surgeries. Post-operative pain is typically controlled with narcotic analgesics such as morphine, but systemic administration of these drugs can result in unfavorable side effects including suppression of breathing, sedation, nausea and vomiting; and can also affect patient recovery. Innocoll's BUPIVACAINE SURGICAL IMPLANT is intended to provide pain control directly at the surgical site and thus reduce the level of additional analgesia required following surgery. The collagen matrix naturally biodegrades over a few days and the bupivacaine is released to provide local analgesia for up to 96 hours post-operatively. A key feature of Innocoll's product is the ability to implant it directly into the surgical cavity and at different layers within the wound, such as across the peritoneum incision and directly below the skin incision, which enables localized treatment of both the incisional and deep, visceral pain components in tandem.

The results of an initial clinical study performed at Wexham Park Hospital, Slough, UK, in patients undergoing hysterectomy surgery were particularly encouraging, showing evidence of sustained, post-operative analgesia for approximately 96 hours. Innocoll filed an IND in March 2007 and intends to conduct a series of phase 2, multi-centered, controlled clinical trials in a variety of soft tissue and orthopedic surgical models; including hysterectomy, herniorrhaphy, open gastrointestinal surgery and anterior cruciate ligament (ACL) repair. BUPIVACAINE SURGICAL IMPLANT is believed to offer broad utility across a variety of surgical disciplines, as reflected in independent market research recently performed by L.E.K. Consulting which expects the product to achieve peak US sales nearing US$310 million.

About CollaRx(R) Bupivacaine Topical

CollaRx BUPIVACAINE TOP
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014  Decision Resources Group finds that ... factor (VEGF) agent for wet AMD, is equally likely ... as Genentech,s Lucentis, which is the standard of care ... organization (MCO) directors do not identify a clear clinical ... likely than Lucentis to be listed on tier 1 ...
(Date:9/18/2014)... -- Zacks.com announces the list of stocks featured in the ... discuss the latest news and events impacting stocks and ... include the Avanir Pharmaceuticals (Nasdaq: AVNR - Free Report ... ), Orexigen (Nasdaq: OREX - Free Report ), ... Gilead (Nasdaq: GILD - Free Report ). ...
(Date:9/18/2014)... , Sept. 18, 2014 Veterinary biologic ... Dr. Ashraf Hanna , M.D., Ph.D., and Dr. ... of Directors. Dr. Hanna is the Vice President of ... Financial Officer for the Genentech Foundation, while Dr. McCracken ... of Business Development and Licensing for Roche Pharma. ...
Breaking Medicine Technology:Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3
(Date:9/18/2014)... Amy Norton HealthDay Reporter ... single dose of a common antidepressant can quickly alter the ... The findings, reported online Sept. 18 in ... brain,s response to widely prescribed antidepressants. Experts said the hope ... depression are likely to benefit from a drug -- and ...
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... breeding grounds for microbes -- don,t worry, it,s a ... years, not all microbes are bad. Many active enzymes ... beneficial to humans as an important part of our ... , Candida albicans , an opportunistic yeast pathogen ... doesn,t damage our healthy personal ecosystem. However, when our ...
(Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
(Date:9/18/2014)... September 18, 2014 As testosterone ... in U.S. courts, Bernstein Liebhard LLP notes that ... U.S. Food & Drug Administration (FDA) subject prescription ... implemented, could greatly reduce their use. The joint ... Drug Advisory Committee, and the Drug Safety and ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 3Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 4
... -- A 2005 voluntary federal ban on the use of ... on all commercial shipping of such purchases within the United ... sell cigarettes, new research reveals. The ban was the ... private shippers, such as UPS and FedEx, made primarily to ...
... Reporter , FRIDAY, Feb. 25 (HealthDay News) -- Medical ... unique ways to solve challenging problems. But scientists can ... diseases, particularly when those methods involve animals or insects. ... team, which is studying fruit flies to help determine ...
... a rare disease and recurrent botulism even more rare. ... drug users has been on the rise and makes ... A new study published in Clinical Infectious ... examines this problem. From 1993 through 2006, 17 ...
... (HealthDay News) -- A fresh look at 19th century Mormon marriage ... offspring any one wife produced. "Although it,s great in terms ... that for every new woman added to a male,s household, the ... study author and evolutionary biologist Michael Wade, from Indiana University in ...
... HealthDay Reporter , THURSDAY, Feb. 24 (HealthDay News) ... to warn of impending dangers to human health if ... They believe the federal government, specifically the Environmental Protection ... emissions, however. "The science is unequivocal that global ...
... the 3rd International Conference on innovative approaches in Head ... colleagues at hospitals and institutes in Denmark presented results ... 7 study. The study, conducted across the country, investigated ... radiotherapy treatment for a head & neck cancer. "We ...
Cached Medicine News:Health News:Study Finds Drop in Online Sales of Cigarettes 2Health News:Seeking Alzheimer's Answers Among Fruit Flies 2Health News:Seeking Alzheimer's Answers Among Fruit Flies 3Health News:19th Century Polygamy Meant Fewer Kids Per Wife, Data Shows 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 3Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 4Health News:New way to identify patients at risk of dysphagia after head and neck cancer treatment 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: